Aytu BioPharma to commercialise Exxua for MDD in the US

finance.yahoo.com/news/aytu-biopharma-commercialise-exxua-mdd-113026214.html

In This Article:
Aytu BioPharma has signed an exclusive agreement with Fabre-Kramer Pharmaceuticals to commercialise Exxua (gepirone) extended-release tablets, a new antidepressant, to the US market for major depressive disorder (MDD).
Exxua, developed by Fabre-Kramer Pharmaceuticals, is…

This story appeared on finance.yahoo.com, 2025-06-09 11:30:26.
The Entire Business World on a Single Page. Free to Use →